Charles River Laboratories Stock Surges On Upbeat Annual Outlook, But This Analyst Is Concerned

Charles River Laboratories International Inc (NYSE:CRL) reported fourth-quarter 2023 revenue of $1.01 billion, a decrease of 7.9% Y/Y, beating the consensus of $991.25 million.

The impact of foreign currency translation benefited reported revenue by 1.2%, and acquisitions contributed 0.7% to consolidated fourth-quarter revenue. Organic revenue decreased 3.5%. 

Adjusted operating margin decreased to 19.1% from 20.4%.

Adjusted net income was $127.2 million for the fourth quarter of 2023, a decrease of 16.8% from a year ago. Adjusted EPS of $2.46 surpassed the consensus estimate of $2.40.

“Despite moderating demand trends in the broader life sciences sector, we were able to deliver solid revenue growth and non-GAAP earning per share that were in …

Full story available on Benzinga.com